Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/13/2022 | $21.00 | Buy | Ladenburg Thalmann |
| 3/2/2022 | $14.00 | Buy | HC Wainwright & Co. |
Fort Lee, NJ, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium. Event2024 Ladenburg Virtual Oncology Innovators & Investors SymposiumDate12 December 2024Time10 am EST About Nuvectis Pharma, Inc. Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicin
NXP800 demonstrated single agent activity New dosing schedule successfully minimized thrombocytopenia Fort Lee, NJ, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported encouraging data from the Phase 1b study evaluating NXP800 in patients with platinum resistant ARID1a-mutated ovarian cancer. Platinum-resistant, ARID1a-mutated ovarian cancer is a serious condition that carries a poor prognosis with an estimated life expectancy of approximately one year from diagnosis.
Clinical data update from the NXP800 Phase 1b study expected this month; NXP800 granted Orphan Drug Designation for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancersNXP900 Phase 1a dose escalation study progressing as planned, 4 escalation cohorts completed with no DLTs, dose escalation continues FORT LEE, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the third quarter
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
Ladenburg Thalmann initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $21.00
HC Wainwright & Co. initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $14.00
S-8 - Nuvectis Pharma, Inc. (0001875558) (Filer)
10-Q - Nuvectis Pharma, Inc. (0001875558) (Filer)
8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4/A - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
SC 13G/A - Nuvectis Pharma, Inc. (0001875558) (Subject)
SC 13G/A - Nuvectis Pharma, Inc. (0001875558) (Subject)
SC 13G - Nuvectis Pharma, Inc. (0001875558) (Subject)